European Journal of Cardiovascular Medicine

Background:  Nonalcoholic fatty liver disease (NAFLD) is frequently linked to metabolic aberrant disorders including diabetes and elevated triglycerides (TGs). As of now, nonalcoholic fatty liver disease has no authorized pharmacotherapy. The treatment of diabetic dyslipidemia with saroglitazar, the first licensed dual PPAR α and γ agonist in the world, was approved in India. This study's goal was to determine whether saroglitazar, 4 mg once daily, is safe and effective in lowering glycemic markers and liver fibrosis in individuals with type 2 diabetic mellitus (T2DM) who also had nonalcoholic fatty liver disease (NAFLD). Objective:  To evaluate the efficacy of saroglitazar therapy in patients with non-alcoholic fatty liver disease. Materials and methods: The study was carried out at IGIMS, Patna. A total of 122 patients with raised liver enzymes and non-alcoholic fatty liver disease coming to IGIMS Hospital, Patna were enrolled in the study. This was a prospective, cross-sectional observational real-world study. all the participants took saroglitazar 4 mg daily once. liver enzymes were measured before and after 3 months of treatment with saroglitazar. Results: There was a significant improvement in serum triglyceride and liver enzymes at three months of treatment. Conclusion: Saroglitazar therapy is an effective therapy for non-alcoholic fatty liver disease.